The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
嘻嘻哈哈
林狗
平常迎天
GingerF
YifanWang
淡然元彤
学霸业
山野下
无极微光
DIVINEDC
herococa
逍遥
amorfati
sml
tuanheqi
神勇映雁
清爽老九
loii
OK
DW
皖公网安备34019202002308
